Key Points
- CEO Craig Parker sold 4,524 shares on May 4 at an average price of $33.33 for proceeds of $150,784.92, reducing his ownership by 21.46% to 16,553 shares (≈$551,711).
- The company posted a major earnings miss — Q1 EPS ($7.59) vs. ($1.29) expected with $0.53M revenue — and the stock trades in a one‑year range of $5.90–$35.00 with a market cap of about $375M and severely negative profitability metrics.
- Analysts are mixed but tilted positive: MarketBeat shows a consensus of "Moderate Buy" with an average target of $38.00, while individual ratings range from Sell to Strong Buy.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) CEO Craig Parker sold 4,524 shares of the firm's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $150,784.92. Following the completion of the sale, the chief executive officer owned 16,553 shares in the company, valued at approximately $551,711.49. This represents a 21.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Surrozen Stock Performance
NASDAQ:SRZN opened at $32.64 on Wednesday. Surrozen, Inc. has a 1 year low of $5.90 and a 1 year high of $35.00. The stock has a market cap of $375.03 million, a P/E ratio of -0.98 and a beta of 0.59. The stock has a 50-day simple moving average of $28.27 and a 200-day simple moving average of $22.11.
Surrozen (NASDAQ:SRZN - Get Free Report) last issued its earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing the consensus estimate of ($1.29) by ($6.30). The business had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.66 million. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 7,476.67%. On average, equities research analysts predict that Surrozen, Inc. will post -4.04 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on SRZN shares. Wall Street Zen upgraded shares of Surrozen from a "sell" rating to a "hold" rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a research report on Tuesday, April 21st. Cantor Fitzgerald reiterated an "overweight" rating and set a $40.00 price target on shares of Surrozen in a research note on Tuesday, March 24th. TD Cowen initiated coverage on shares of Surrozen in a research note on Tuesday, April 21st. They issued a "buy" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective (up from $32.00) on shares of Surrozen in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $38.00.
View Our Latest Report on Surrozen
Institutional Investors Weigh In On Surrozen
Large investors have recently modified their holdings of the company. Boothbay Fund Management LLC purchased a new position in shares of Surrozen during the fourth quarter worth approximately $414,000. Quadrature Capital Ltd purchased a new stake in Surrozen in the 4th quarter valued at $335,000. OMERS ADMINISTRATION Corp acquired a new stake in Surrozen during the 4th quarter worth $310,000. Geode Capital Management LLC boosted its stake in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock worth $277,000 after purchasing an additional 5,702 shares during the period. Finally, Marshall Wace LLP purchased a new position in Surrozen during the 4th quarter worth $247,000. 66.57% of the stock is owned by institutional investors and hedge funds.
About Surrozen
(
Get Free Report)
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
